top of page
Browse by category
Search
Tirzepatide was superior to placebo for MASH resolution
Results from Eli Lilly and Company’s SYNERGY-NASH that evaluated the investigational use of tirzepatide in adults with biopsy-proven...
BMS associated with lower all-cause mortality compared with GLP-1RA treatment
Bariatric metabolic surgery (BMS) was associated with lower all-cause mortality compared with glucagon-like peptide-1 receptor agonists...
BRIDGE Study: Bariatric surgery as a bridge to facilitate neoplastic/cancer surgery
Metabolic and bariatric surgery (MBS) offers a promising role as a transformative procedure prior to neoplastic therapy for patients...
Experts issue nutritional recommendations for patients treated with anti-obesity medications
Individuals treated with anti-obesity medications generally experience reduced appetite, which typically leads to reduced food intake. As...
Home-administered treatment for binge eating disorder shows promising results
Researchers from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London, UK, have investigated the...
Journal Watch 5/06/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
ASGARD Trial: BPD-DS may not be a better surgical strategy than RYGB for patients with a BMI 50-60
The ten-year outcomes from the ’Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Biliopancreatic Diversion (BPD)- Duodenal...
GLP-1 receptor agonist drugs are effective but come with complex concerns
Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) are highly effective for weight management and Type 2 diabetes treatment,...
GLP-1 medications safe to continue before surgery in patients with diabetes and obesity
There are only mild differences in gastric emptying among patients taking glucagon-like peptide-1 (GLP-1) receptor agonist medications...
First patient treated in phase 2 obesity trial of GLY-200 polymer
Glyscend Therapeutics has initiated a Phase 2 clinical trial of its lead candidate, GLY-200, as a novel oral treatment for obesity....
Browse by tag
bottom of page